Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience

Sawalha, Yazeed; Hill, Brian T.; Rybicki, Lisa; Sun, Di; Dean, Robert M.; Jagadeesh, Deepa; Hamilton, Betty K.; Gerds, Aaron T.; Sobecks, Ronald; Andrèsen, Steven; Liu, Hien K.; Majhail, Navneet S.; Pohlman, Brad; Kalaycio, Matt; Bolwell, Brian J.; Smith, Mitchell R.

doi:10.1016/j.clml.2017.11.002

Cited by 6 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our population, 34 of the 70 patients under 65 years were identified for ASCT; of these 22 had the procedure, one patient refused, and harvest attempts were unsuccessful for 10, a similar failure rate to that reported by others (Kuittinen et al , ). Indeed, the difficulty of achieving stem cell mobilisation in MCL compared to other non‐Hodgkin lymphomas has been noted by others, particularly among those previously treated with Hyper‐CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate) (Hill et al , ; Kurnaz & Kaynar, ; Sawalha et al , ) .…”

Section: Discussionmentioning

confidence: 99%

Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)

et al. 2018

View full text Add to dashboard Cite

SummaryThe treatment landscape for mantle cell lymphoma (MCL) has changed dramatically in recent years, with findings from clinical trials reporting improvements in survival. Data on the general patient population are, however, sparse; and it is unclear whether the effects observed in clinical trials have translated into the real‐world setting. To investigate this, we examined first‐line and relapsed/refractory (RR) disease management in 335 MCL patients diagnosed between 2004 and 2015 in an established population‐based patient cohort, along with data on demographic, diagnostic and prognostic factors. Marked treatment and survival changes were observed; first‐line rituximab immunotherapy, for example, increased from 32% to 86% over the 11‐year period, and median survival increased from 2·0 years among those first treated in 2004–2011 to 3·5 years among those treated in 2012–2015. Outcomes for RR disease also improved, from 8 months in 2004–2011 to 16·8 months in 2012–2015, coinciding with the introduction of agents, such as bendamustine and ibrutinib. Encouragingly, improvements were seen across all ages; 1‐year overall survival among patients over 70 years treated for RR disease almost doubled. Our analyses underscore the importance of monitoring the impact of treatment changes in the real‐world setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The benefit of HD-ASCT in MCL is currently under debate 12 . MCL patients treated with HD-ASCT have shown better progression-free 5,6,[13][14][15][16] and overall survival 17,18 compared to non-HD-ASCT treated, but mainly prior to the era of rituximab maintenance and the role of HD-ASCT in the era of novel targeted drugs is unclear.…”

Section: Introductionmentioning

confidence: 99%

Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation

et al. 2023

View full text Add to dashboard Cite

Studies on late effects in mantle cell lymphoma (MCL) patients are increasingly important as survival is improving and novel targeted drugs are being introduced, however knowledge about late effects is limited. The aim of this population-based study was to describe the magnitude and panorama of late effects among patients treated with or without high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT). The study cohort included all MCL patients, recorded in the Swedish Lymphoma Register, 18-69 years old, diagnosed 2000-2014 (total n=620, treated with HD-ASCT n=247) and 1:10 matched healthy comparators. Patients and comparators were followed via the national Patient Register and Cause-of-Death-Register, from 12 months after diagnosis/matching until December 2017. Incidence rate ratios of numbers of outpatient visits, hospitalizations and bed days were estimated using negative binomial regression models. In relation to the matched comparators, the rate of specialist and hospital visits was significantly higher among MCL patients (IRR 2.0, 95% CI: 1.8-2.2 and 7.2, 95% CI: 6.3-8.3, respectively). MCL patients had especially high relative risks of infectious, respiratory and blood disorders. Within this observation period, no difference in rate of these complications, including secondary neoplasms, was observed between HD-ASCT and non-HD-ASCT treated patients. The majority of patients died from their lymphoma and not from another cause or treatment complication. Taken together, our results imply that the vast majority of the post-treatment healthcare needs are related to the lymphoma disease itself, thus, indicating the need for more efficient treatment options.

show abstract

Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study

Li,

Chang,

Liu

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience

Cited by 6 publications

References 29 publications

Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)

Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)

Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation

Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study

Contact Info

Product

Resources

About